References |
1 |
Exploration of inhibition potential of isoniazid and its metabolites towards CYP2E1 in human liver microsomes through LC-MS/MS analysis J Pharm Biomed Anal. 2021 Sep 5;203:114223. doi: 10.1016/j.jpba.2021.114223.
|
2 |
Molecular mechanism for the activation of the potent hepatotoxin acetylhydrazine: Identification of the initial N-centered radical and the secondary C-centered radical intermediates. Free Radic Biol Med. 2023 Aug 1;204:20-27. doi: 10.1016/j.freeradbiomed.2023.04.010.
|
3 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS. Molecules. 2022 Dec 6;27(23):8607. doi: 10.3390/molecules27238607.
|
4 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis. Br J Clin Pharmacol. 2023 Feb;89(2):714-726. doi: 10.1111/bcp.15527.
|
5 |
In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans
|
6 |
Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog
|